Benitec Biopharma announced this week that a challenge to a key UK patent has been withdrawn, and that the amended claims in the patent have been accepted by the United Kingdom Intellectual Property Office.

According to the company, the patent — GB 2353282 — had been challenged in 2010 by a UK-based law firm on behalf of an unknown client. Benitec said it responded to all the issues raised in the challenge, deciding to “slightly amend” the IP to “provide greater clarity, in particular that the claims were to double-stranded constructs.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.